Human beings are big data. We aren’t just 175 pounds of meat and bone. We aren’t just piles of hydrogen and carbon and oxygen. What makes us all different is how it’s all organized and that is information. We can no longer treat people based on simple numbers like weight, pulse, blood pressure, and temperature. What makes us different is much more complicated than that. . . .
→ Read full post: Is Medicine a Big Data Problem?
source: by Timothy Hay
When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes.
But it was more of a flesh wound, said Claremont Creek Ventures Director Ted Driscoll. Though not an investor in 23andMe, he has . . .
→ Read full post: Ted Driscoll’s WSJ interview: 23andMe Flap With FDA Just a Bump in the Road, One Genetics-Testing Investor Says
Our portfolio company Assurex Health just announced the creation of a partnership with Canada’s Center for Addiction and Mental Health (CAMH), one of the world’s leading research centers in the area of addiction and mental health and Canada’s largest mental health teaching hospital. CAMH will offer to Canadian citizens the firm’s pharmacogenomic test, GeneSight, which is now widely available in the US. Claremont Creek Ventures is very excited about this step . . .
→ Read full post: Assurex Health Launches Collaboration with Canadian Mental Health Center
Our portfolio company NuMedii just announced a groundbreaking collaboration with Thomson Reuters, the world’s leading information provider for businesses. The Thomson Reuters Science division has quietly been aggregating an enormous database of biological, clinical, and pharmacological information over the past few years. As a biotech startup, NuMedii is focused on revolutionizing drug discovery by reducing the incredible inefficiencies and costs involved in small molecule drug development.
The drug development process is . . .
→ Read full post: Thomson Reuters and NuMedii Launch Initiative for Drug Discovery
Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry.
The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing discussions within the Psychiatric community about the value of laboratory testing in . . .
→ Read full post: Assurex Health Publishes Seminal Paper on Pharmacogenomics
Our portfolio company Genalyte just announced the award of a government grant from the National Cancer Institute for the development of a diagnostic system using Genalyte’s proprietary biomarker technology (see Genalyte Expands into Cancer Profiling with $1 Million NCI Grant to Develop Cancer Biomarker Panel). This project is a significant validation of the company’s capability to assay blood biomarkers using the multiplex Maverick detection platform, which provides rapid, accurate, . . .
→ Read full post: Genalyte Receives National Cancer Institute Grant
Atul J. Butte, M.D., Ph.D.
Big Data Guru and Stanford Medical School Professor Atul Butte, co-founder of Numedii had his work recently profiled in the journal SCIENCE. As the article claims, the explosion of publicly available databases housing sequences, structures, and images allows life scientists to make fundamental discoveries without ever getting their hands “wet” at the lab bench. Science . . .
→ Read full post: Numedii co-founder Atul Butte featured in Science article on “Dry Biology” research
Congratulations to our portfolio company NuMedii for a publication today in Cancer Discovery, which discusses the use of its technology by Stanford researchers to identify an antidepressant as a potential treatment for small cell lung cancer.
NuMedii is a pioneer in the future of pharmacology. As medicine becomes more personalized, every individual will get a custom treatment matched to their genetic and proteomic makeup and pathways. The old way of developing . . .
→ Read full post: Numedii discovers repurposed antidepressants have potential to treat small cell lung cancer
Earlier this week one of our portfolio companies, Genalyte, Inc., announced the release of a groundbreaking diagnostic system for early detection of Type 1 diabetes. This is of special significance to me as the young daughter of a good friend almost died due to undiagnosed Type 1 Diabetes – she was discovered by her parents in a low blood sugar coma in the middle of the night and rushed to . . .
→ Read full post: Genalyte and Colorado Diabetes Center Collaborate on Type 1 Diabetes
Top 5 pathways to personalized medicine
Healthcare IT NewsJeff RoweJuly 22, 2013
If there’s one thing everyone in healthcare can probably agree on right now, it’s that there is an awful lot of data being generated each and every day. What to do with that data, however, is another question.
As Ted Driscoll, digital health director at venture capital firm Claremont Creek Ventures, sees it, the explosion of data is a definite boon . . .
→ Read full post: Ted Driscoll interview in Health Care IT News “Top 5 pathways to personalized medicine”